Todd Carter
Vermogen: 510 013 $ op 30-06-2026
Vermogen: 510 013 $ op 30-06-2026
Todd Carter is currently Chief Scientific Officer at Voyager Therapeutics, Inc. since 2022.
Formerly, Dr. Carter was Senior Director-Biology at BrainCells, Inc. Education includes a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from Texas A&M University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 24-02-2026 | 145.718 ( 0,24% ) | 510 013 $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-11-2018 |
| Bedrijven | Functie | Einde |
|---|---|---|
BrainCells, Inc.
BrainCells, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
BrainCells, Inc.
BrainCells, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Health Technology |
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Texas A&M University
Texas A&M University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau